Zuranolone is being evaluated as a short course, rapid-acting, oral medication for major depressive disorder (MDD) and postpartum depression (PPD) Cambridge, Mass. – Dec. 6, 2022– Biogen Inc. (Nasdaq: BIIB) and Sage Therapeutics…Original Article
Biogen and Sage Therapeutics Complete Rolling Submission of New Drug Application for Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression
